When you think “healthcare,” the first place your mind probably goes is Best Buy, right?

No? Well, perhaps that’s a good thing, seeing as it recently divested from its hospital-at-home offering and restructured its health business.

In 2021, the tech retailer acquired the Current Health virtual care platform for roughly $400 million, and in 2023, it shared plans to further develop its healthcare services. But the company’s health arm struggled, recording a Q4 $475 million goodwill impairment charge, which contributed to a nearly 16% stock drop on March 4 and led to a healthcare restructuring that included an announcement to lay off 161 employees, effective this September.

Current Health announced the split from Best Buy at the end of June. It will be reacquired by co-founder Christopher McGhee, who started the company in 2014, for an unspecified amount. According to a LinkedIn post, Current Health treated 70,000+ patients during its time under the Best Buy umbrella and had partnerships with major health systems like New York-based Mount Sinai Health System and NYU Langone Health.

Don’t call it a trend (yet).—NO

Amid regulatory uncertainties, high utilization, and changing marketplace rules, payers aren’t doing great right now.

UnitedHealth was the first to retract its prediction for its annual performance in May after Medicare Advantage utilization surpassed its highest expectations. Now, it’s Centene’s turn in the spotlight.

What happened? Centene pulled its 2025 revenue guidance on July 1 after actuarial firm Wakely predicted fewer people would get Affordable Care Act (ACA) marketplace coverage than expected, and those who did would be sicker—and costlier.

Wakely’s analysis included 22 of Centene’s 29 marketplace states, making up about 72% of the company’s individual marketplace plan members. The company reported that as of March 31, it had 5.6 million marketplace members.

Here’s what’s going on with Centene.—CC

Sarepta Therapeutics is laying off 36% of staff—500 employees—a move expected to be “substantially completed” by the end of Q3, it announced in a July 16 8-K filing.

As part of these changes, the company is scrambling its C-suite:

• The company is terminating Dallan Murray, EVP and chief customer officer, though he will remain a consultant through January 2026.
• Ian Estepan, former EVP and CFO, is now president and chief operating officer.
• Former president and CEO Douglas Ingram will solely be CEO from now on.
• Ryan Wong has taken over Estepan’s old positions.
• Louise Rodino-Klapac is now the company’s president of R&D and technical operations. She was previously EVP and chief scientific officer, and headed R&D.

Sarepta will also add a black-box warning—the most serious kind—for acute liver injury and failure for Elevidys, per the FDA’s request. Elevidys, the company’s most profitable product, is the only FDA-approved gene therapy for deadly muscle-wasting disease Duchenne muscular dystrophy.

See the latest here.—CC